Jachym is a co-founder of April19 Discovery, a biotech startup where they accelerate the drug discovery process with the help of AI and apply their innovative methods in the development of the next generation of psychedelics. A substantial part of April19's drug development campaign is stemming from nearly 4 years of his own research at UCT Prague and UCL, where he has been designing and synthesizing a novel class of neuroplasticity-inducing drugs with a unique pharmacological profile. They believe these compounds have the potential to be highly effective in treating mental and neurodegenerative disorders while also being safer, less hallucinogenic and allowing daily use due to lower tolerance buildup. 

Jachym's academic and professional careers are devoted to helping people overcome their suffering by discovering and bringing to practice revolutionary health treatments. His strongest expertise is in the field of neuropsychiatric health where he focuses mainly on the potentiation of neuroplasticity and neurogenesis, especially using psychedelic-inspired drugs. Coming from a strong medicinal chemistry background, he has transitioned into computational chemistry and computer-aided drug design.